Demant A/S (CPH:DEMANT)
201.00
+1.00 (0.50%)
Apr 29, 2026, 10:46 AM CET
Demant Revenue
In the year 2025, Demant had annual revenue of 22.97B DKK with 2.46% growth. Demant had revenue of 11.72B in the half year ending December 31, 2025, with 7.44% growth.
Revenue
22.97B
Revenue Growth
+2.46%
P/S Ratio
1.84
Revenue / Employee
916.02K
Employees
26,704
Market Cap
42.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.97B | 552.00M | 2.46% |
| Dec 31, 2024 | 22.42B | 818.00M | 3.79% |
| Dec 31, 2023 | 21.60B | 1.90B | 9.62% |
| Dec 31, 2022 | 19.71B | 1.80B | 10.05% |
| Dec 31, 2021 | 17.91B | 3.44B | 23.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.21B |
| ALK-Abelló | 6.31B |
| Bavarian Nordic | 6.24B |
Demant News
- 6 days ago - Reminder - Waterdrop (WDH) Goes Ex-Dividend Soon - Nasdaq
- 3 months ago - Demant Earnings Call Transcript: Q4 2025 - Transcripts
- 6 months ago - Demant Earnings Call Transcript: Q3 2025 - Transcripts
- 9 months ago - Demant Earnings Call Transcript: Q2 2025 - Transcripts
- 11 months ago - Demant Transcript: M&A Announcement - Transcripts
- 11 months ago - Demant Transcript: M&A Announcement (Media) - Transcripts
- 1 year ago - Demant Earnings Call Transcript: Q1 2025 - Transcripts
- 1 year ago - Demant Earnings Call Transcript: Q4 2024 - Transcripts